Dana-Farber Cancer Institute Completes Record-Breaking $2.5 Billion Fundraising Campaign
Key Insights
Dana-Farber Cancer Institute concluded a seven-year fundraising campaign, raising a record $2.5 billion to advance cancer (search) research and patient care.
The funds will support clinical trials, enhance cancer (search) care equity programs, and facilitate the expansion of medical facilities to improve patient access.
A new integrated clinic was launched to focus on early detection and prevention of cancer (search) in high-risk individuals, utilizing novel technologies.
Dana-Farber Cancer Institute has announced the completion of a historic fundraising campaign, securing $2.5 billion to bolster its efforts in cancer (search) research and patient care. This seven-year initiative, known as The Dana-Farber Campaign, has significantly enhanced the institute's capacity to conduct revolutionary science and provide exceptional care to a growing number of patients.
The campaign's success has already translated into tangible advancements across several key areas. Clinical trial programs have expanded by more than 22%, now offering over 1,100 active trials. These trials, many of which are philanthropically supported, are crucial for developing new cancer (search) treatments.
Enhancing Cancer Care Equity
Dana-Farber has more than doubled the size of its Cancer (search) Care Equity Program, enabling greater support for patients from medically underserved communities. The institute currently has over 90 active clinical research studies and pilot programs focused on understanding and eliminating disparities in cancer care.
Expansion of Facilities and Patient Volume
In the past five years, Dana-Farber has opened three new patient care facilities, bringing the total to seven. This expansion has allowed the institute to serve over 96,000 patients in the past year, a 26% increase since 2019.
Focus on Early Detection and Prevention
In 2023, Dana-Farber launched an integrated clinic dedicated to the early detection of precancerous conditions and the prevention of cancer (search) in high-risk individuals. These centers are developing novel technologies and methods for earlier cancer detection and intervention.
"It has been an honor to lead this historic campaign that has allowed Dana-Farber to make great strides in cancer (search) research and patient care," said Laurie H. Glimcher, MD, former President and CEO of Dana-Farber. "I am grateful to the many benefactors whose generosity and dedication have enabled remarkable progress in the ambitious effort to find cures for cancer."
Benjamin Ebert, MD, PhD, the newly appointed President and CEO of Dana-Farber, expressed optimism for the future, stating, "The vast community of support during this campaign helped exceed our lofty goals, enabling breakthroughs in the laboratory and the development of life-saving therapies for cancer (search) patients. While the incidence of cancer is rising in the U.S., I am hopeful for the future and inspired by the new treatments that are transforming cancer care."